Arrowhead Pharmaceuticals Inc. (ARWR)
86.78
-1.92 (2.16%)
Upcoming Events
Latest Headlines
Arrowhead Pharma (ARWR) PT Raised to $120 at Morgan Stanley
July 23, 2026 8:42 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)
July 23, 2026 7:10 AM - StreetInsider
Arrowhead Pharma (ARWR) PT Raised to $126 at Piper Sandler
July 23, 2026 6:51 AM - StreetInsider
Arrowhead's plozasiran hits Phase 3 endpoints in triglyceride study
July 22, 2026 7:30 AM - StreetInsider
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
July 22, 2026 7:30 AM - BizWire
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
July 21, 2026 7:30 AM - BizWire
Stifel Starts Arrowhead Pharma (ARWR) at Buy
July 13, 2026 4:07 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)
July 2, 2026 6:43 AM - StreetInsider
EU approves Arrowhead's plozasiran for rare triglyceride disorder
June 22, 2026 12:36 PM - StreetInsider
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
June 22, 2026 12:33 PM - BizWire
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
June 18, 2026 7:30 AM - BizWire
Form 4 ARROWHEAD PHARMACEUTICAL For: Jun 15 Filed by: Cohen Matthew Gregory
June 17, 2026 9:44 PM - SEC Filing
Form 3 ARROWHEAD PHARMACEUTICAL For: Jun 15 Filed by: Cohen Matthew Gregory
June 17, 2026 9:44 PM - SEC Filing
Arrowhead Pharmaceuticals appoints Dr. Matt Cohen to its board of directors
June 16, 2026 4:07 PM - StreetInsider
Form 8-K ARROWHEAD PHARMACEUTICAL For: Jun 12
June 16, 2026 4:03 PM - SEC Filing
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
June 2, 2026 7:30 AM - BizWire
Arrowhead presents obesity drug data showing liver fat reduction
May 27, 2026 7:00 AM - StreetInsider
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
May 27, 2026 7:00 AM - BizWire
Arrowhead presents plozasiran data supporting use without dose adjustment
May 26, 2026 10:00 AM - StreetInsider
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
May 26, 2026 10:00 AM - BizWire
Form 144/A ARROWHEAD PHARMACEUTICAL Filed by: Apel Daniel Joseph
May 19, 2026 4:46 PM - SEC Filing
Form 144/A ARROWHEAD PHARMACEUTICAL Filed by: Lu Hongbo
May 19, 2026 4:44 PM - SEC Filing
Form 144/A ARROWHEAD PHARMACEUTICAL Filed by: Hamilton James C
May 19, 2026 4:40 PM - SEC Filing
Form 4 ARROWHEAD PHARMACEUTICAL For: May 12 Filed by: Lu Hongbo
May 14, 2026 7:06 PM - SEC Filing
Arrowhead Pharma (ARWR) PT Raised to $46 at Bernstein SocGen Group
May 13, 2026 7:15 AM - StreetInsider
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Lu Hongbo
May 12, 2026 4:35 PM - SEC Filing
Arrowhead Pharma (ARWR) PT Raised to $87 at RBC Capital
May 8, 2026 7:26 AM - StreetInsider
Form S-8 ARROWHEAD PHARMACEUTICAL
May 7, 2026 5:28 PM - SEC Filing
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31
May 7, 2026 4:07 PM - SEC Filing
Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 11c
May 7, 2026 4:04 PM - StreetInsider
Form 8-K ARROWHEAD PHARMACEUTICAL For: May 07
May 7, 2026 4:03 PM - SEC Filing
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
May 7, 2026 4:01 PM - BizWire
Form SCHEDULE 13G ARROWHEAD PHARMACEUTICAL Filed by: FMR LLC
May 6, 2026 11:02 AM - SEC Filing
Arrowhead licenses liver disease drug to Madrigal for $25 million upfront
May 5, 2026 8:03 AM - StreetInsider
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 5, 2026 8:00 AM - BizWire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
May 4, 2026 7:30 AM - BizWire
Arrowhead receives Australia approval for rare disease drug REDEMPLO
May 1, 2026 7:30 AM - StreetInsider
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
May 1, 2026 7:30 AM - BizWire
JPMorgan Starts Arrowhead Pharma (ARWR) at Overweight
May 1, 2026 1:56 AM - StreetInsider
Form SCHEDULE 13G ARROWHEAD PHARMACEUTICAL Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 4:46 PM - SEC Filing
Form SCHEDULE 13G ARROWHEAD PHARMACEUTICAL Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
April 28, 2026 4:06 PM - SEC Filing
Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 22 Filed by: Apel Daniel Joseph
April 24, 2026 6:45 PM - SEC Filing
Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 23 Filed by: Hamilton James C
April 24, 2026 6:39 PM - SEC Filing
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc.
April 24, 2026 4:13 PM - SEC Filing
ARWR receives positive EU opinion for REDEMPLO to treat rare genetic disorder
April 24, 2026 6:39 AM - StreetInsider
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
April 24, 2026 6:39 AM - BizWire
Full Article List
